Netherlands Cancer Institute (NCI)

22 articles about Netherlands Cancer Institute (NCI)

• LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

  10/16/2023

  LIXTE Biotechnology Holdings, Inc. announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.

• Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

  7/17/2023

  LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW) today announced that a recently posted article in BioRxiv ( https://www.biorxiv.org/content/10.1101/2023.07.12.548685v1 ), based on the results of a collaboration between the Company and the Netherlands Cancer Institute, shows that inhibition of PP2A in colon cancer cells, using LIXTE’s lead clinical compound LB-100, leads to major changes in the way cancer cells process their mRNAs.

• New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer Institute

  3/9/2020

  Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations

• Give way to the immune system

  10/26/2018

  Physicians can possibly use immunotherapy in cancer patients more effectively. More and more voices are in favor of giving this new treatment before the surgeon removes a tumor instead of afterwards. This could have huge benefits, like a better immune response against the tumor. On 22 October,  researcher Christian Blank and his colleagues at the Netherlands Cancer Institute presented the results of a new study among melanoma patients at the ESMO conference.

• 

  Neon Therapeutics to Launch IPO at $16 Per Share

  6/27/2018

  Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.

• The Netherlands Cancer Institute Awarded Funding To Apply Molecular Imaging Technology To Prostate Cancer Surgery

  10/17/2017

  The Netherlands Cancer Institute (NKI) announced today that it has received funding from the Dutch Cancer Society (KWF Kankerbestrijding) to test whether a novel molecular imaging technology can guide prostate cancer surgery.

• Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics

  10/4/2017

• Elekta And Royal Philips Electronics N.V. Begin Installation Of MR-Guided Linear Accelerator At The Netherlands Cancer Institute (NCI)

  4/18/2016

• Neon Therapeutics Enters Collaborative Research Agreement With The Netherlands Cancer Institute (NCI)

  2/23/2016

• Internationally Renowned Netherlands Cancer Institute (NCI)-Antoni Van Leeuwenhoek Hospital Acquires Elekta's Leksell Gamma Knife Icon

  12/1/2015

• Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NCI)

  9/14/2015

• Kite Pharma Announces Publication In Science Of Cancer Immunotherapy Articles Authored By Lead Collaborators At The National Cancer Institute And The Netherlands Cancer Institute (NCI)

  4/6/2015

• FORMA Therapeutics, Inc. Acquires Covalent Chemistry Platform From Netherlands Cancer Institute (NCI)

  5/5/2014

• Elekta and Netherlands Cancer Institute (NCI) -Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research

  6/8/2012

• Delcath Systems, Inc. Announces Agreement With Netherlands Cancer Institute (NCI)-Antoni van Leeuwenhoek Hospital for Training and Launch of Hepatic Chemosat Delivery System

  4/10/2012

• Non-Drug Treatments Help Alleviate Symptoms of Treatment-Induced Menopause in Breast Cancer Patients, Netherlands Cancer Institute (NCI) Study

  3/23/2012

• New Genomic Test Spares Patients Chemotherapy With No Adverse Effect on Survival, Netherlands Cancer Institute (NCI) Study

  3/22/2012

• Combination Of PET/CT Tests Can Expedite Diagnosis Of Lung Cancer In A Fast-Track Setting, Netherlands Cancer Institute (NCI) Study

  10/2/2009

• Agendia BV's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute (NCI) - AVL

  2/4/2009

• Silicone Breast Implants Might Raise Risk of Rare Lymphoma, Netherlands Cancer Institute (NCI) Study

  11/5/2008